Get notified when BMRA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Dilution Per Share to New Investors In This Offering $0.11 (new) — The prospectus discloses immediate dilution of $0.11 per share based on an assumed offering price of $0.6138, but the authoritative computed figure is $0.04 per share at the final price of $0.61; either way, new investors pay more than the net tangible book value per share.
Biomerica launches at-the-market offering of up to $5.5M at $0.61/share, netting $5.3M
Filed May 10, 2024 · ~1 min read
Key Changes
-
high
Biomerica is selling up to $5.5 million of common stock through an at-the-market facility with EF Hutton and R.F. Lafferty, at a final price of $0.61 per share.
The Offering verify on EDGAR → -
high
Net proceeds to the company are $5.3 million after commissions and expenses; the company will use them for general corporate purposes including sales, marketing, clinical studies, product development, and working capital.
Use of Proceeds verify on EDGAR → -
high
New investors face immediate dilution of $0.04 per share, based on the offering price and the company's net tangible book value.
Dilution verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (CMC 10-K) is open in full — no account needed.
Partner
Trade BMRA commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 3, 2026 · How we verify